(Q24245099)

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Phenothiazine-induced ECG abnormalities: effect of a glucose load

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Evidence of Brain Dopamine Deficiency in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

THE COMPARATIVE EFFECTIVENESS OF AMITRIPTYLINE, PERPHENAZINE, AND THEIR COMBINATION IN THE TREATMENT OF CHRONIC PSYCHOTIC FEMALE PATIENTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

METHIONINE EFFECTS ON CHRONIC SCHIZOPHRENICS: PATIENTS TREATED WITH MONOAMINE OXIDASE INHIBITORS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

Role of antidepressants and neuroleptics in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

CPT and VCRT performances as functions of imipramine and nialamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Citalopram augmentation of antipsychotic treatment in older schizophrenia patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

MODALINE SULFATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Viloxazine and the depressed schizophrenic--methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Issues in the meta-analysis of cluster randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Evaluation of trifluperidol in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Psychiatric diagnosis and a typology of clinical drug effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Histories of substance abuse in patients with postpsychotic depressions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Metabolic interaction between amitriptyline and perphenazine in psychiatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

The reliability of distinguishing primary versus secondary negative symptoms.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluoxetine as an add-on medication to typical antipsychotics in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

1 reference

7 January 2021

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Self-administration of medication by psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluoxetine Augmentation of Haloperidol in Chronic Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Nialamide in the treatment of chronic schizophrenia in geriatric patients: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Pipotiazine palmitate (19.552 R.P.) in the long-term treatment of chronic psychoses. A controlled trial on in-patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Effects of Control Techniques on Therapeutic Outcome in a Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

The use of triflupromazine with iproniazid for the treatment of chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipiramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Perphenazine-Amitriptyline in the Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Platelet monoamine oxidase activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Implications of the efficacy of thiothixene and a chlorpromazine- imipramine combination for depression in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Postpsychotic depression and negative symptoms: an investigation of syndromal overlap

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A simple and reliable subclassification of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

A Double-Blind Trial of Amitriptyline/Perphenazine, Perphenazine and Placebo in Chronic Withdrawn Inert Schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Trials of Lithium, Chlorpromazine and Amitriptyline in Schizoaffective Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Interface between authorship, industry and science in the domain of therapeutics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

Tranquilizers or Anti-Depressants for Chronic Schizophrenics: A Long Term Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005581.PUB2

7 January 2021

10.1002/14651858.CD005581.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2401978

2401978

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference